Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Temozolomide × 90 days × Clear all

Sponsor

Conditions

Glioblastoma 48 Glioma 14 Brain Neoplasms 14 Neuroblastoma 10 Sarcoma, Ewing 8 Gliosarcoma 8 Astrocytoma 8 Medulloblastoma 7 Sarcoma 6 Rhabdomyosarcoma 6 Ependymoma 6 Recurrence 5 Osteosarcoma 5 Neoplasms 5 Melanoma 5 Diffuse Intrinsic Pontine Glioma 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Oligodendroglioma 3 Neoplasm Metastasis 3 Lymphoma 3 Colorectal Neoplasms 3 Wilms Tumor 2 Somatostatinoma 2 Rhabdoid Tumor 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroectodermal Tumors, Primitive 2 Lymphoma, Follicular 2

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡